Locatelli, Francesco (7202821585)Francesco (7202821585)LocatelliDimkovic, Nada (6603958094)Nada (6603958094)DimkovicSpasovski, Goce (6602271573)Goce (6602271573)Spasovski2025-06-122025-06-122014https://doi.org/10.1517/14656566.2014.928285https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902269402&doi=10.1517%2f14656566.2014.928285&partnerID=40&md5=6e3a0cd81c88be575f5e2a7f883cd219https://remedy.med.bg.ac.rs/handle/123456789/8779Introduction: Hyperphosphataemia is common in chronic kidney disease (CKD), particularly in the late stages and is associated with secondary hyperparathyroidism, abnormal bone mineralisation and increased cardiovascular morbidity/mortality. At present, there is a range of phosphate binders designed to keep serum phosphate at normal or near normal levels. Colestilan is a new binder that offers additional actions that may afford further benefits over simply lowering phosphate.Areas covered: This paper reviews the pharmacology and clinical data currently available in the use of colestilan to treat hyperphosphataemia in CKD stage 5 patients on dialysis.Expert opinion: Available phosphate binders lower serum phosphorus levels to a clinically relevant extent. The balance between the risks and the potential benefits associated with each agent must be considered when choosing a binder. Calcium-based binders can lead to hypercalcaemia and/or positive calcium balance and cardiovascular calcification. Like sevelamer, colestilan is not absorbed and there is no evidence of any risk of hypercalcaemia. In addition, a significant lowering of low-density lipoprotein-cholesterol, similar to simvastatin, a reduction in plasma uric acid and a reduction in high glycosylated haemoglobin values suggest additional beneficial actions that may convert to reductions in mortality. © 2014 Informa UK, Ltd.Chronic kidney diseaseColestilanDialysisHyperphosphataemiaPhosphate binderTolerability